Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03018249 · ClinicalTrials.gov registry record · Early Phase 1
Medroxyprogesterone Acetate With or Without Entinostat Before Surgery in Treating Patients With Endometrioid Endometrial Cancer
A Early Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Early Phase 1
- Development phase
- 50
- Enrollment target
NCT03018249: Completed Early Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT03018249 is a Early Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 50 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03018249, a Early Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 50 participants
- Enrollment target
Study Summary
This randomized surgical window trial evaluates the effect of adding entinostat to medroxyprogesterone acetate before surgery works on progesterone receptors on endometrioid endometrial tumors. Medroxyprogesterone acetate is a progesterone, a hormone produced by body normally. Entinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving medroxyprogesterone acetate with or without entinostat may effect tumors from endometrioid endometrial cancer.
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Entinostat
- PROCEDURE Hysterectomy
- DRUG Medroxyprogesterone Acetate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2017-10-11 |
| Est. Completion | 2021-03-12 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03018249
The ClinicalTrials.gov registry entry for NCT03018249 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT03018249 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03018249 about?
NCT03018249 is a clinical study titled "Medroxyprogesterone Acetate With or Without Entinostat Before Surgery in Treating Patients With Endometrioid Endometrial Cancer". This randomized surgical window trial evaluates the effect of adding entinostat to medroxyprogesterone acetate before surgery works on progesterone receptors on endometrioid endometrial tumors. Medroxyprogesterone acetate is a progesterone, a hormone produced by body normally. Entinostat may stop th...
What is the current status of trial NCT03018249?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 50 participants. The study started on 2017-10-11. Estimated completion is 2021-03-12.
What interventions are being tested in trial NCT03018249?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Entinostat (DRUG), Hysterectomy (PROCEDURE), Medroxyprogesterone Acetate (DRUG).
Who is sponsoring clinical trial NCT03018249?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.